Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127967) titled 'Trastuzumab Rezetecan in Combination with Furmonertinib for the Treatment of Non-Small Cell Lung Cancer with HER-2 Overexpression After Progression on EGFR-TKIs' on July 10.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine
Condition:
Non-Small Cell Lung Cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-07-15
Target Sample Size: Test group:39;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=331859
Published by HT Digital ...